Disgraced researcher blames GSK pressure for Chinese data lapses

GlaxoSmithKline ($GSK) wasn't the only Big Pharma company to set up R&D operations in China. But a feature in Bloomberg today highlights GSK's unusual decision to give its research division there the lead role in neuroscience drug development. Now, a researcher who left the company under a cloud blames a high-pressure corporate culture that insists on quick results for much of what went wrong. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.